Alpha 2.0

» Articles » PMID: 15113859

Evidence That Protease Activated Receptor 2 Expression is Enhanced in Human Coronary Atherosclerotic Lesions

Overview

Overview

Journal J Clin Pathol

Specialty Pathology

Date 2004 Apr 29

PMID 15113859

Citations 15

Authors

Authors

C Napoli

F De Nigris

J L Wallace

M D Hollenberg

G Tajana

G De Rosa

V Sica

G Cirino

Affiliations

Affiliations

Soon will be listed here.

Abstract

Aim: To investigate protease activated receptor 2 (PAR-2) expression in human coronary atherosclerotic lesions because PAR-2 is involved in the modulation of inflammatory events and vascular function.

Methods: An immunohistochemical analysis was performed on serial arterial sections, using the following antibodies: MDA2, a murine monoclonal antibody against malondialdehyde lysine epitopes of oxidised low density lipoprotein (oxLDL); HAM-56, a monoclonal antibody against human macrophages/foam cells; B5, a rabbit polyclonal antibody against PAR-2; and SAM11, a mouse monoclonal antibody against human PAR-2. Sections containing at least one lesion showing substantial immunostaining were counted as positive, and results were expressed as per cent of all sections of the same artery.

Results: PAR-2 expression was enhanced in human coronary atherosclerotic lesions. This phenomenon correlated with an increase in oxLDL epitopes in the coronary artery.

Conclusion: This study shows for the first time that PAR-2 expression is enhanced in human coronary atherosclerotic lesions, and suggests that PAR-2 dependent cellular trafficking may be one of the regulatory signalling responses to vascular injury. Further pharmacological studies will establish whether modulation (and in which direction) of PAR-2 represents a possible therapeutic target for controlling the vascular response to injury.

Citing Articles

Protease-activated receptors in vascular smooth muscle cells: a bridge between thrombo-inflammation and vascular remodelling.

Habibi A, Ruf W, Schurgers L Cell Commun Signal. 2025; 23(1):57.

PMID: 39891111 PMC: 11786455. DOI: 10.1186/s12964-025-02066-6.

Protease-Activated Receptors (PARs): Biology and Therapeutic Potential in Perioperative Stroke.

Mavridis T, Choratta T, Papadopoulou A, Sawafta A, Archontakis-Barakakis P, Laou E Transl Stroke Res. 2024; .

PMID: 38326662 DOI: 10.1007/s12975-024-01233-0.

Protease-Activated Receptor 2 Controls Vascular Smooth Muscle Cell Proliferation in Cyclic AMP-Dependent Protein Kinase/Mitogen-Activated Protein Kinase Kinase 1/2-Dependent Manner.

Williams M, Bullock M, Johnson S, Holland N, Vuncannon D, Oswald J J Vasc Res. 2023; 60(4):213-226.

PMID: 37778342 PMC: 10614497. DOI: 10.1159/000532032.

Upregulation of Protease-Activated Receptor 2 Promotes Proliferation and Migration of Human Vascular Smooth Muscle Cells (VSMCs).

Wei M, Liu Y, Zheng M, Wang L, Ma F, Qi Y Med Sci Monit. 2019; 25:8854-8862.

PMID: 31756174 PMC: 6883764. DOI: 10.12659/MSM.917865.

Protease Activity in Vascular Disease.

Slack M, Gordon S Arterioscler Thromb Vasc Biol. 2019; 39(10):e210-e218.

PMID: 31553665 PMC: 6764587. DOI: 10.1161/ATVBAHA.119.312413.

References

1.

Sabri A, Muske G, Zhang H, Pak E, Darrow A, Andrade-Gordon P . Signaling properties and functions of two distinct cardiomyocyte protease-activated receptors. Circ Res. 2000; 86(10):1054-61. DOI: 10.1161/01.res.86.10.1054. View

2.

Napoli C, Glass C, Witztum J, Deutsch R, DArmiento F, Palinski W . Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) study. Lancet. 1999; 354(9186):1234-41. DOI: 10.1016/S0140-6736(99)02131-5. View

3.

Cirino G, Napoli C, Bucci M, Cicala C . Inflammation-coagulation network: are serine protease receptors the knot?. Trends Pharmacol Sci. 2000; 21(5):170-2. DOI: 10.1016/s0165-6147(00)01469-3. View

4.

Hamilton J, Frauman A, Cocks T . Increased expression of protease-activated receptor-2 (PAR2) and PAR4 in human coronary artery by inflammatory stimuli unveils endothelium-dependent relaxations to PAR2 and PAR4 agonists. Circ Res. 2001; 89(1):92-8. DOI: 10.1161/hh1301.092661. View

5.

Napoli C, De Nigris F, Palinski W . Multiple role of reactive oxygen species in the arterial wall. J Cell Biochem. 2001; 82(4):674-82. DOI: 10.1002/jcb.1198. View

6.

DArmiento F, Bianchi A, De Nigris F, Capuzzi D, DArmiento M, Crimi G . Age-related effects on atherogenesis and scavenger enzymes of intracranial and extracranial arteries in men without classic risk factors for atherosclerosis. Stroke. 2001; 32(11):2472-9. DOI: 10.1161/hs1101.098520. View

7.

McLean P, Aston D, Sarkar D, Ahluwalia A . Protease-activated receptor-2 activation causes EDHF-like coronary vasodilation: selective preservation in ischemia/reperfusion injury: involvement of lipoxygenase products, VR1 receptors, and C-fibers. Circ Res. 2002; 90(4):465-72. DOI: 10.1161/hh0402.105372. View

8.

Napoli C, de Nigris F, Cicala C, Wallace J, Caliendo G, Condorelli M . Protease-activated receptor-2 activation improves efficiency of experimental ischemic preconditioning. Am J Physiol Heart Circ Physiol. 2002; 282(6):H2004-10. DOI: 10.1152/ajpheart.00909.2001. View

9.

Milia A, Salis M, Stacca T, Pinna A, Madeddu P, Trevisani M . Protease-activated receptor-2 stimulates angiogenesis and accelerates hemodynamic recovery in a mouse model of hindlimb ischemia. Circ Res. 2002; 91(4):346-52. DOI: 10.1161/01.res.0000031958.92781.9e. View

10.

McGuire J, Dai J, Andrade-Gordon P, Triggle C, Hollenberg M . Proteinase-activated receptor-2 (PAR2): vascular effects of a PAR2-derived activating peptide via a receptor different than PAR2. J Pharmacol Exp Ther. 2002; 303(3):985-92. DOI: 10.1124/jpet.102.040352. View

11.

Jin E, Fujiwara M, Pan X, Ghazizadeh M, Arai S, Ohaki Y . Protease-activated receptor (PAR)-1 and PAR-2 participate in the cell growth of alveolar capillary endothelium in primary lung adenocarcinomas. Cancer. 2003; 97(3):703-13. DOI: 10.1002/cncr.11087. View

12.

de Nigris F, Lerman A, Ignarro L, Williams-Ignarro S, Sica V, Baker A . Oxidation-sensitive mechanisms, vascular apoptosis and atherosclerosis. Trends Mol Med. 2003; 9(8):351-9. DOI: 10.1016/s1471-4914(03)00139-4. View

13.

Hirano K, Kanaide H . Role of protease-activated receptors in the vascular system. J Atheroscler Thromb. 2003; 10(4):211-25. DOI: 10.5551/jat.10.211. View

14.

Hwa J, Ghibaudi L, Williams P, Chintala M, Zhang R, Chatterjee M . Evidence for the presence of a proteinase-activated receptor distinct from the thrombin receptor in vascular endothelial cells. Circ Res. 1996; 78(4):581-8. DOI: 10.1161/01.res.78.4.581. View

15.

Nystedt S, Ramakrishnan V, Sundelin J . The proteinase-activated receptor 2 is induced by inflammatory mediators in human endothelial cells. Comparison with the thrombin receptor. J Biol Chem. 1996; 271(25):14910-5. DOI: 10.1074/jbc.271.25.14910. View

16.

Danesh J, Collins R, Peto R . Chronic infections and coronary heart disease: is there a link?. Lancet. 1997; 350(9075):430-6. DOI: 10.1016/S0140-6736(97)03079-1. View

17.

Napoli C, DArmiento F, Mancini F, Postiglione A, Witztum J, Palumbo G . Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J Clin Invest. 1998; 100(11):2680-90. PMC: 508471. DOI: 10.1172/JCI119813. View

18.

Molino M, Raghunath P, Kuo A, Ahuja M, Hoxie J, Brass L . Differential expression of functional protease-activated receptor-2 (PAR-2) in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1998; 18(5):825-32. DOI: 10.1161/01.atv.18.5.825. View

19.

Hamilton J, Nguyen P, Cocks T . Atypical protease-activated receptor mediates endothelium-dependent relaxation of human coronary arteries. Circ Res. 1998; 82(12):1306-11. DOI: 10.1161/01.res.82.12.1306. View

20.

Lourbakos A, Chinni C, Thompson P, Potempa J, Travis J, Mackie E . Cleavage and activation of proteinase-activated receptor-2 on human neutrophils by gingipain-R from Porphyromonas gingivalis. FEBS Lett. 1998; 435(1):45-8. DOI: 10.1016/s0014-5793(98)01036-9. View